Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 11/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751319 | 0.87 | MAPK1 (0.41) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5752325 | 0.86 | CETP (0.45) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5749378 | 0.85 | MDM2 (0.48) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5755387 | 0.83 | MDM2 (0.42) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5750278 | 0.83 | CETP (0.48) | MAPK1L3MBTL1TSHRTDP1CETP | |
| SCHEMBL5751599 | 0.83 | MAPK1 (0.41) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5750388 | 0.82 | MAPK1 (0.42) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5752360 | 0.82 | L3MBTL1 (0.41) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5753775 | 0.82 | MAPK14 (0.47) | MAPK1L3MBTL1TSHRTDP1CETP | |
| SCHEMBL5753498 | 0.81 | L3MBTL1 (0.47) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | MAPK1 2140/4885L3MBTL1 2527/4885TSHR 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.